Amgen Inc (NAS:AMGN)
$ 312.47 -2.25 (-0.71%) Market Cap: 167.62 Bil Enterprise Value: 221.93 Bil PE Ratio: 44.64 PB Ratio: 33.37 GF Score: 90/100

Amgen Inc Conference Call from ASCO Transcript

Jun 04, 2021 / 08:00PM GMT
Release Date Price: $236.85 (+0.47%)
Operator

I'm the operator today for Amgen's conference call from ASCO. (Operator Instructions) I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.

Arvind Sood
Amgen Inc. - VP of IR

Thank you, Erica. Good afternoon, everyone. Welcome, and we very much appreciate your participation in our ASCO event. We have presented important data at this conference and very much looking forward to the discussion. Presenting from Amgen will be our Executive Vice President of Research and Development, Dr. David Reese, who will briefly review our oncology portfolio strategy, followed by our Vice President of Global Development, Dr. Greg Friberg. Greg will review the Lumakras data in non-small cell lung cancer followed by Dr. P.K. Morrow, who is also a Vice President of Global Development. P.K. will then review the bemarituzumab data in gastric cancer and Tarlatamab data in small cell lung cancer.

Tarlatamab, by the way, is our DLL3 targeting BiTE also known as AMG 757. Don't worry about taking pictures of the slides as a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot